Marine Biomedical, a strategic partner of Orthocell, has received US Food and Drug Administration (FDA) 510(k) clearance for PearlBone, a bone graft substitute made from pearl shell sourced sustainably from Western Australia's Kimberley region. The FDA clearance allows PearlBone to be marketed in the United States for its intended indications, marking a significant milestone for both companies as they aim to enter one of the world's largest medical device markets. Orthocell, an Australian biotech company listed on the ASX (ASX:OCC), finalized a strategic investment in Marine Biomedical in January 2026, increasing its equity stake to 12% through a $1.05 million investment. This investment also secured Orthocell a first right of refusal over global distribution rights for PearlBone and future bone repair and regeneration products. PearlBone leverages the natural properties of nacre, the biomineralized structure of pearl shell, to support bone repair and regeneration. The product is manufactured at Marine Biomedical's purpose-built facility in Broome, Western Australia, which supports the development of advanced biomedical manufacturing capabilities in regional Australia. Orthocell's CEO, John Van Der Wielen, stated that the FDA clearance represents a significant step toward unlocking the potential of PearlBone in the global bone repair and regeneration market. He emphasized that the investment was made with the strategic objective of securing exposure to innovative bone regeneration technology that complements Orthocell's existing nerve and tendon repair portfolio. Marine Biomedical is now advancing preparations for the US launch, including manufacturing readiness, market development, and engagement with potential commercial and clinical partners. The clearance enables Orthocell to leverage its established relationships with US surgeons, distributors, and commercial infrastructure to support PearlBone's market introduction. PearlBone has potential applications across orthopedic, trauma, and reconstructive surgery, positioning it for broad market adoption. This development follows Orthocell's recent success in recording its strongest monthly US Remplir sales since launch, indicating growing market acceptance for its products in the United States.

Shenzhen, China, Oct. 10, 2026 /PRNewswire/ — Shenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (SpO2) measurement (Clearance No. K260490). This clearance marks a significant milestone for RingConn in the FDA-cleared wearable health device space. RingConn has undergone FDA regulatory review and has been determined to be substantially equivalent to legally marketed predicate devices for non-invasive measurement of blood oxygen (SpO2). This clearance provides compliance assurance for RingConn’s expansion into the U.S. healthcare and wellness market, and further […]

Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures.

GE HealthCare (GEHC) received FDA 510(k) clearance on Apr 5, 2026 for Photonova Spectra CT; vendors cite up to 60% dose reduction and significant long-term service revenue potential.

Lantern Pharma won FDA clearance on Mar 27, 2026 to start a Phase 1 pediatric DIPG trial; DIPG carries median survival under 12 months and ~200–400 US cases/year.

RapidAI bolsters its clinical AI platform with new FDA-cleared modules designed to enhance neurology, vascular, and radiology care.

California med-tech firm Rapid Nexus secures FDA clearance for Hemastyl, a device targeting the root cause of chronic non-healing wounds.

RapidAI bolsters its clinical AI platform with new FDA-cleared modules designed to enhance neurology, vascular, and radiology care.

California med-tech firm Rapid Nexus secures FDA clearance for Hemastyl, a device targeting the root cause of chronic non-healing wounds.

Movano Health (Nasdaq: MOVE) has achieved a significant milestone with the U.S.